HMGB1 and myeloid sarcoma: Neutralization of HMGB1 appears to be a novel strategy against MS as evidenced by an experimental study of MS, where anti-HMGB1 mAb ameliorated clinical severity, reduced CNS pathology, and blocked the production of pro-inflammatory cytokine (Uzawa et al., 2013).